English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background  The Schistosomiasis Consortium for Operational Research and Evaluation (SCORE) focus is on randomized trials of different approaches to mass drug administration (MDA) in endemic countries in Africa. Because their studies provided an opportunity to evaluate the effects of mass treatment on  Schistosoma -associated morbidity, nested cohort studies were developed within SCORE’s intervention trials to monitor changes in a suite of schistosomiasis disease outcomes. This paper describes the process SCORE used to select markers for prospective monitoring and the baseline prevalence of these morbidities in four parallel cohort studies.    Methods  In July 2009, SCORE hosted a discussion of the potential impact of MDA on morbidities due to  Schistosoma  infection that might be measured in the context of multi-year control. Candidate markers were reviewed and selected for study implementation. Baseline data were then collected from cohorts of children in four country studies: two in high endemic  S. mansoni  sites (Kenya and Tanzania), and two in high endemic  S. haematobium  sites (Niger and Mozambique), these cohorts to be followed prospectively over 5 years.    Results  At baseline, 62% of children in the  S. mansoni  sites had detectable eggs in their stool, and 10% had heavy infections (≥ 400 eggs/g feces). Heavy  S. mansoni  infections were found to be associated with increased baseline risk of anemia, although children with moderate or heavy intensity infections had lower risk of physical wasting. Prevalence of egg-positive infection in the combined  S. haematobium  cohorts was 27%, with 5% of individuals having heavy infection (≥50 eggs/10 mL urine). At baseline, light intensity  S. haematobium  infection was associated with anemia and with lower scores in the social domain of health-related quality-of-life (HRQoL) assessed by Pediatric Quality of Life Inventory.    Conclusions  Our consensus on practical markers of  Schistosoma -associated morbidity indicated that height, weight, hemoglobin, exercise tolerance, HRQoL, and ultrasound abnormalities could be used as reference points for gauging treatment impact. Data collected over five years of program implementation will provide guidance for future evaluation of morbidity control in areas endemic for schistosomiasis.    Trial registration  These cohort studies are registered and performed in conjunction with the International Standard Randomised Controlled Trial Registry trials  ISRCTN16755535 ,  ISRCTN14117624 ,  ISRCTN95819193 , and  ISRCTN32045736 .    Electronic supplementary material  The online version of this article (10.1186/s12879-017-2738-5) contains supplementary material, which is available to authorized users.

bmc infectious diseases

Protocol and baseline data for a multi-year cohort study of the effects of different mass drug treatment approaches on functional morbidities from schistosomiasis in four African countries